These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11558695)

  • 1. The controversy over high-dose chemotherapy with autologous bone marrow transplant for breast cancer.
    Mello MM; Brennan TA
    Health Aff (Millwood); 2001; 20(5):101-17. PubMed ID: 11558695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Litigating the science of breast cancer treatment.
    Jacobson PD; Rettig RA; Aubry WM
    J Health Polit Policy Law; 2007 Oct; 32(5):785-818. PubMed ID: 17855717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New approach to administrative medical decision-making: evidence-based medicine using high dose chemotherapy/bone marrow transplant for breast cancer.
    Lucey C; Westphal JR
    South Med J; 1998 Feb; 91(2):196-201. PubMed ID: 9496875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABMT and breast cancer.
    Firshein J
    Healthplan; 1999; 40(4):30-3, 35-7. PubMed ID: 10557735
    [No Abstract]   [Full Text] [Related]  

  • 5. Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support.
    Winer EP; Lindley C; Hardee M; Sawyer WT; Brunatti C; Borstelmann NA; Peters W
    Psychooncology; 1999; 8(2):167-76. PubMed ID: 10335560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspectives. Indefinite results in ABMT (autologous bone marrow transplantation) trials add to challenges for practice standards, quality assurance in cancer care.
    Cunningham R
    Med Health; 1999 Apr; 53(16):suppl 1-4. PubMed ID: 10387749
    [No Abstract]   [Full Text] [Related]  

  • 7. Health insurance: coverage of autologous bone marrow transplantation for breast cancer.
    Jaggar SF
    Oncology (Williston Park); 1996 Sep; 10(9):1329-32, 1337-8, 1340 passim. PubMed ID: 8882925
    [No Abstract]   [Full Text] [Related]  

  • 8. Experimental medical treatments: who should decide coverage?
    Collins JC
    Spec Law Dig Health Care Law; 1998 Jan; (226):9-45. PubMed ID: 10176412
    [No Abstract]   [Full Text] [Related]  

  • 9. High-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) for the treatment of breast cancer: the jury is still out.
    Smith GA; Henderson IC
    Important Adv Oncol; 1995; ():201-14. PubMed ID: 7672807
    [No Abstract]   [Full Text] [Related]  

  • 10. ABMT and breast cancer: what have we learned?
    Brown E
    Physician Exec; 1999; 25(4):86-8. PubMed ID: 10557495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer coverage. Why are insurers paying for this "experimental" therapy?
    Med Econ; 1996 Sep; 73(17):38. PubMed ID: 10161873
    [No Abstract]   [Full Text] [Related]  

  • 12. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer.
    Eddy DM
    J Clin Oncol; 1992 Apr; 10(4):657-70. PubMed ID: 1285731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer.
    Peters WP; Rogers MC
    N Engl J Med; 1994 Feb; 330(7):473-7. PubMed ID: 8289855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental medical treatments: who should decide coverage?
    Collins JC
    Seattle Univ Law Rev; 1997; 20(2):451-87. PubMed ID: 16528856
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results.
    Hillner BE; Smith TJ; Desch CE
    JAMA; 1992 Apr; 267(15):2055-61. PubMed ID: 1552641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current legal intervention regarding "experimental" treatments must be changed: an analysis of high doses of chemotherapy with autologous bone marrow transplantation for breast cancer patients.
    Smayda E
    J Law Health; 1998-1999; 13(2):257-80. PubMed ID: 10947396
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effective use of autologous bone marrow transplantation: few answers, many questions, and suggestions for future assessments.
    Hillner BE; Smith TJ; Desch CE
    Pharmacoeconomics; 1994 Aug; 6(2):114-26. PubMed ID: 10147437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant.
    Laughlin MJ; McGaughey DS; Crews JR; Chao NJ; Rizzieri D; Ross M; Gockerman J; Cirrincione C; Berry D; Mills L; Defusco P; LeGrand S; Peters WP; Vredenburgh JJ
    J Clin Oncol; 1998 Mar; 16(3):1008-12. PubMed ID: 9508184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Smith TJ; Hillner BE; Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Link H; Zander A; Yanovich S; Kitchin R; Erder MH
    J Clin Oncol; 1997 Jan; 15(1):5-10. PubMed ID: 8996118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No place for politics.
    Fee K
    Mod Healthc; 2000 May; 30(21):48, 50. PubMed ID: 11067549
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.